Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer, reviews the potential treatment options, including PARP inhibitors, and highlights the importance of genetic testing when selecting treatment regimens.
EP. 1: Case Presentation: A 64-Year-Old Man with Metastatic Prostate Cancer
Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer and a BRCA2 mutation.
EP. 2: Typical Presentations of Metastatic Prostate Cancer and Risk of Disease Progression
Dr Neal Shore gives his first impressions of a patient case and gauges the risk of progression.
EP. 3: The Utility of Genetic Testing in Patients with Prostate Cancer
An expert urologist highlights the vital importance of genetic testing in cases of prostate cancer.
EP. 4: Mutations in HRR-Related Genes in Prostate Cancer
A focused discussion on the significance of mutations in homologous recombination repair (HRR)-related genes in prostate cancer.
EP. 5: Available Treatment Options for Chemotherapy-Naïve mCRPC
Neal Shore, MD, explains the available first-line treatment options for chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).
EP. 6: Olaparib Safety and Efficacy Data from the PROfound Trial
An overview of safety and efficacy data from the phase 3 PROfound trial evaluating the PARP inhibitor olaparib.
EP. 7: A Urologist’s Treatment Selection for Metastatic Prostate Cancer
Dr Neal Shore shares how he would have treated the patient with metastatic prostate cancer from the presented case.
EP. 8: Potential Use of PARP Inhibitors for First-Line Treatment of mCRPC
A review of whether PARP inhibitors such as olaparib could potentially be used in earlier lines of therapy for mCRPC.
EP. 9: Current Challenges and Future Directions in Metastatic Prostate Cancer
Neal Shore, MD, FACS, muses about the unmet needs in metastatic prostate cancer treatment and shares clinical pearls for community oncologists.
2 Clarke Drive Cranbury, NJ 08512